Cardiology News and Research

Latest Cardiology News and Research

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery (MINS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak oxygen consumption compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when given on top of individually optimized lipid-lowering therapy, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

AMALFI trial finds small increase in AF diagnosis with mail-based ECG patch monitoring

A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at moderate-to-high stroke risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in JAMA (The Journal of the American Medical Association).

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

$Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction$

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of patients with MI and mildly reduced left ventricular ejection fraction (LVEF), according to an individual patient data meta-analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

First ESC statement on mental health and heart disease promotes integrated care

A new ESC Clinical Consensus Statement is calling for greater awareness of the multidirectional relationship between mental health conditions and cardiovascular disease to improve patient health.

30 Aug 2025

Updated guidelines aim to standardize valvular heart disease care across Europe

Updated ESC/EACTS Guidelines, being published today at ESC Congress 2025, aim to improve the way that patients with valvular heart disease are diagnosed and treated, responding to robust new evidence that suggests some newer and less invasive treatments could be offered more widely and consistently to patients.

30 Aug 2025

New ESC guidelines introduce unified approach to improve myocarditis and pericarditis care

New ESC Guidelines to improve the diagnosis and care of patients with myocarditis and pericarditis, have been published today at ESC Congress 2025.

30 Aug 2025

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC/EAS Focused Update to Guidelines, about how best to manage lipid levels in patients to reduce cardiovascular risk, recommends the use of new cardiovascular risk predication algorithms. The update was published today at ESC Congress 2025.

30 Aug 2025

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Updated ESC Guidelines, published today at ESC Congress 2025, put a focus on a woman's autonomy in making her own reproductive choices by promoting a transparent dialogue and shared decision-making for pregnancies that are high-risk for an adverse maternal and/or fetal event.

30 Aug 2025

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Beta blockers-drugs commonly prescribed for a range of cardiac conditions, including heart attacks-provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function.

30 Aug 2025

Daily use of low-dose colchicine may slow growth of blood mutations linked to disease

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published in JACC, the flagship journal of the American College of Cardiology, and simultaneously presented at ESC Congress 2025.

29 Aug 2025

Predictable music phrases found to regulate blood pressure

A new study has found that blood pressure synchronises to predictable phrase structures in music. Blood pressure was more affected by loudness than tempo and was more strongly influenced by phrase structures that were more predictable.

29 Aug 2025

Herpes zoster vaccination linked to lower risk of heart attack and stroke

A new global systematic literature review and meta-analysis has shown that herpes zoster vaccination, used to prevent shingles, is associated with a statistically significant lower risk of heart attack and stroke.

29 Aug 2025

Inflammation marker can help identify heart risk in women without traditional factors

Cardiologists have long known that up to half of all heart attacks and strokes occur among apparently healthy individuals who do not smoke and do not have high blood pressure, high cholesterol, or diabetes, the "standard modifiable risk factors" which doctors often call "SMuRFs."

29 Aug 2025

Cardiology News and Research

Latest Cardiology News and Research

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

AMALFI trial finds small increase in AF diagnosis with mail-based ECG patch monitoring

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

First ESC statement on mental health and heart disease promotes integrated care

Updated guidelines aim to standardize valvular heart disease care across Europe

New ESC guidelines introduce unified approach to improve myocarditis and pericarditis care

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Daily use of low-dose colchicine may slow growth of blood mutations linked to disease

Predictable music phrases found to regulate blood pressure

Herpes zoster vaccination linked to lower risk of heart attack and stroke

Inflammation marker can help identify heart risk in women without traditional factors

Forensics and toxicology - Industry Focus eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cardiology News and Research

Latest Cardiology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in